VEGFA and neoplasm: In the second line of treatment, the patients are given inhibitors of tyrosine kinases, mainly the VEGF receptor (VEGFR), and in the third, everolimus—an inhibitor of serine-threonine kinase mTOR (mammalian target of rapamycin kinase)—which reduces VEGF concentration and inhibits the growth and multiplication of tumor cells [19,20].